Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Transcode Therapeutics Inc
(NQ:
RNAZ
)
0.2750
+0.0050 (+1.85%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Transcode Therapeutics Inc
< Previous
1
2
3
Next >
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
August 15, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics, Inc. Announces Closing of Public Offering
July 24, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics, Inc. Announces Pricing of Public Offering
July 22, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
July 22, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
June 10, 2024
TransCode shares to remain listed on Nasdaq
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
May 29, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Open Letter to Shareholders
May 13, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
April 15, 2024
Clinical trial expected to commence in mid-2024 to evaluate the safety and preliminary anti-tumor activity of TTX-MC138
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Reports 2023 Results; Provides Business Update
April 03, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
March 28, 2024
Medical oncologist brings over 25 years of industry experience to lead Clinical Development Strategy
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
March 11, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
March 06, 2024
Highlights TTX-MC138’s Path from Target Discovery to the Clinic
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
February 20, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
January 31, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
January 29, 2024
Project to test combination of TransCode’s proprietary TTX delivery platform and Debiopharm’s drug delivery technologies
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
January 22, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
January 18, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
January 12, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
January 11, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
January 04, 2024
Despite Difficult Financial Markets, TransCode Raised New Capital and Initiated Its First Clinical Trial With Its Lead Therapeutic Candidate, A First-in-Class Compound Designed to Treat Metastatic...
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
December 12, 2023
TTX-MC138 is Effective in Animal Models of Human Metastatic Pancreatic Cancer
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
December 05, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
December 04, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
November 30, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
November 14, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Withdraws Public Offering
October 30, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions
October 27, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Public Offering of Common Stock
October 26, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138
October 26, 2023
Suggests potential to improve survival outcomes in patients with GBM
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138
October 24, 2023
Evidence of Drug Accumulation in Metastatic Lesions
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.